These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 7088259

  • 1. [Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
    Lacour B, Di Giulio S, Nicolaï A, Drüeke T, Debray M, Boulu RG.
    Nephrologie; 1982; 3(1):19-22. PubMed ID: 7088259
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis.
    Sakai T, Maruyama T, Imamura H, Shimada H, Otagiri M.
    J Pharmacol Exp Ther; 1996 Aug; 278(2):786-92. PubMed ID: 8768732
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
    Merk W, Graben N, Hartmann H, Nikolaus C, Schlierf G, Schwandt P.
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):59-62. PubMed ID: 3557732
    [Abstract] [Full Text] [Related]

  • 5. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y, Takabatake Y, Oka K, Shoji T, Togawa M, Okada N, Takahito I, Imai E.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [Abstract] [Full Text] [Related]

  • 6. The use of clofibrate in patients with renal insufficiency.
    Viikari J, Anttila M, Kasanen A.
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929
    [Abstract] [Full Text] [Related]

  • 7. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis.
    Asad SN, Olmer AJ, Letteri JM.
    Miner Electrolyte Metab; 1984 Feb; 10(5):333-6. PubMed ID: 6493162
    [Abstract] [Full Text] [Related]

  • 8. Plasma protein binding of zolpidem in liver and renal insufficiency.
    Pacifici GM, Viani A, Rizzo G, Carrai M, Ganansia J, Bianchetti G, Morselli PL.
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):439-43. PubMed ID: 3198298
    [Abstract] [Full Text] [Related]

  • 9. Unchanged protein binding of penbutolol in renal insufficiency: a possible role of carbamylation.
    Aguirre C, Calvo R, Rodriguez-Sasiain JM.
    Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):31-4. PubMed ID: 8444514
    [Abstract] [Full Text] [Related]

  • 10. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ, Lindup WE.
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [Abstract] [Full Text] [Related]

  • 11. The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency.
    Grafnetterová J, Vodrázka Z, Jandová D, Schück O, Tomásek R, Lachmanová J.
    Clin Nephrol; 1976 Oct; 6(4):448-50. PubMed ID: 975643
    [Abstract] [Full Text] [Related]

  • 12. Binding of tiaprofenic acid to human sera and isolated serum proteins.
    Nilsen OG, Storhaug A, Dale O.
    Arzneimittelforschung; 1985 Oct; 35(6):984-7. PubMed ID: 4026926
    [Abstract] [Full Text] [Related]

  • 13. [Studies on the competition of several antibiotics for binding sites to serum protein (author's transl)].
    Malerczyk V, Ruegenberg W, Seiler KU, Simon C.
    Arzneimittelforschung; 1979 Oct; 29(2):169-71. PubMed ID: 582125
    [Abstract] [Full Text] [Related]

  • 14. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences.
    Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, De Santo NG.
    J Am Soc Nephrol; 2004 Oct; 15(10):2747-54. PubMed ID: 15466280
    [Abstract] [Full Text] [Related]

  • 15. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.
    Verbeeck RK, De Schepper PJ.
    Clin Pharmacol Ther; 1980 May; 27(5):628-35. PubMed ID: 7371361
    [Abstract] [Full Text] [Related]

  • 16. A new aspect of serum protein binding of tolbutamide.
    Ayanoğlu G, Uihlein M, Grigoleit HG.
    Int J Clin Pharmacol Ther Toxicol; 1986 Feb; 24(2):65-8. PubMed ID: 3957494
    [Abstract] [Full Text] [Related]

  • 17. Endogenous accumulation products and serum protein binding in uremia.
    McNamara PJ, Lalka D, Gibaldi M.
    J Lab Clin Med; 1981 Nov; 98(5):730-40. PubMed ID: 7299243
    [Abstract] [Full Text] [Related]

  • 18. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients?
    Lindgren BF, Odar-Cederlöf I, Ericsson F, Brismar K.
    Growth Regul; 1996 Sep; 6(3):137-43. PubMed ID: 8894646
    [Abstract] [Full Text] [Related]

  • 19. Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients.
    Bjornsson TD, Meffin PJ, Peters FA, Blaschke TF.
    Clin Pharmacol Ther; 1980 Feb; 27(2):230-5. PubMed ID: 7353345
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of equilibrium gel filtration chromatography for the study of protein binding of aluminum in normal and uremic sera.
    Bertholf RL, Wills MR, Savory J.
    Clin Physiol Biochem; 1985 Feb; 3(5):271-6. PubMed ID: 4053493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.